Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.

Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Jul 14, 2023

Keywords

ClinConnect Summary

This clinical trial is looking into a condition called wild-type TTR cardiac amyloidosis (wtTTR-CA), which can cause problems with the heart. The researchers want to find out how common this condition is among patients who have chronic nerve damage, known as polyneuropathy, that doesn’t have a clear cause. By understanding this connection better, the goal is to help doctors diagnose wtTTR-CA more quickly, which could lead to better treatment outcomes for patients.

To take part in this study, participants need to be at least 60 years old and have chronic axonal length-dependent polyneuropathy (this is a type of nerve damage affecting long nerves) or small-fiber neuropathy (which affects smaller nerves). They should not have a known cause for their symptoms. The study is open to both men and women, and participants will need to give written consent to join. If someone is interested in this trial, they can expect to undergo assessments related to their nerve condition and contribute to important research that could improve understanding and treatment of heart-related issues connected to nerve damage.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) without well-defined etiology.
• • Age: \>= 60 years
• • Male and female gender
• • Written informed consent
• Exclusion Criteria:
• • Known cause of polyneuropathy
• • Other types of peripheral neuropathy than chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN).
• • Patients younger than 60 years